Spinal Muscular Atrophy Drug Spinraza to be Added to Pharmaceutical Benefits Scheme in Australia!

https://intensivecareathome.com/budget-2018-spinal-muscular-atrophy-drug-spinraza-nusinersen-to-be-added-to-pharmaceutical-benefits-scheme-in-australia/

Budget 2018: Spinal Muscular Atrophy Drug Spinraza (Nusinersen) to be Added to Pharmaceutical Benefits Scheme in Australia!

Book your free 15-minute phone consultation here

http://intensivecarehotline.com/scheduling-appointment/

Call directly 24/7
+1 415-915-0090 USA/Canada
+44 118 324 3018 UK
+6141 094 2230 Australia

Email support@intensivecarehotline.com

Get 1:1 consulting and advocacy
1:1 phone counselling
http://intensivecarehotline.com/one-on-one-counselling/

Become a member for families of critically ill Patients in Intensive Care
https://intensivecarehotline.com/intensivecaresupport-org-membership/

Immediate action steps http://intensivecarehotline.com/take-control-take-charge/immediate-action-steps/
https://intensivecareathome.com

And if you need a medical record review, click on the link and we can help you with reviewing your loved one’s medical records while they’re in ICU.

https://intensivecarehotline.thrivecart.com/review-of-medical-records/

Facebook Page: https://www.facebook.com/ICUhotline
Twitter: https://twitter.com/icuhotline

#icu
#intensivecare
#criticalcare

In this week’s blog I want to share some good news that’s relevant for some of our clients in the community.

Budget 2018: Spinal muscular atrophy drug Spinraza (Nusinersen) to be added to Pharmaceutical Benefits Scheme in Australia!

I know that some of our clients have been waiting for these great news as their kids have been getting the drug as part of a trial! Now Spinraza/Nusinersen is finally on the PBS scheme and affordable.

Rather than paying $375,000 the drug is now available for $39.50 under the PBS scheme.

You can read more about the good news here, it was first published on May 6th on the ABC news website and also in the Sydney Morning Herald

http://www.abc.net.au/news/2018-05-06/spinal-muscular-atrophy-spinraza-pharmaceutical-benefits-scheme/9731138

Children with a muscle-wasting condition called spinal muscular atrophy (SMA) will get a new breakthrough drug for just $40, instead of hundreds of thousands of dollars.

Key points:

Access for life saving drug for genetic condition
The drug Spinraza helps patients with spinal muscular atrophy
More than $240 million to be allocated to fund the drug
Health Minister Greg Hunt told the ABC from June 2018, Spinraza will be available on the Pharmaceutical Benefits Scheme (PBS) for the treatment of Type 1, Type 2 and Type 3a SMA for all patients under the age of 18.

“This will be both life-saving and life-changing for hundreds of young patients and their families,” he said.

SMA is a rare, muscle-wasting genetic disorder that affects the motor neurons that control movement.

The most severe form, Type 1, can cause respiratory problems, extreme weakness and early death.

The disorder is the number one genetic killer in babies.

‘Mackenzie’s mission’ to improve screening and treatment

In January 2018, Mr Hunt revealed his plan to the ABC to boost education, screening and treatment for genetic conditions.

He called it “Mackenzie’s mission” after baby Mackenzie Casella, who died from SMA...

Continue reading at: https://intensivecareathome.com/budget-2018-spinal-muscular-atrophy-drug-spinraza-nusinersen-to-be-added-to-pharmaceutical-benefits-scheme-in-australia/